

THE BURDEN OF ATRIAL FIBRILLATION (AF)

Understanding the Impact of the New Millennium Epidemic across Europe

Report highlights AF as one of Europe's most significant health issues¹

WHAT IS AF?

Atrial fibrillation (AF) is characterized by an irregular and often fast heart rhythm that results in uncoordinated contraction of the top 2 chambers of the heart (the atria).²

THE CHALLENGE OF AF

11 million people affected across Europe.³


By 2050 Europe is projected to have the greatest number of AF patients compared to other regions.⁴

€660 – €3,286 million estimated cost to healthcare systems across European countries.⁵⁻⁸

AF increases the risk of other potentially fatal conditions such as heart failure and stroke.⁹⁻¹⁰

CAUSES OF AF

Abnormalities or damage to the heart's structure are the most common causes of AF.¹¹⁻¹⁴



SYMPTOMS OF AF

Symptoms of AF disrupt normal life and range from mild to debilitating¹⁵⁻¹⁷



15%-30% OF PATIENTS EXPERIENCE **NO SYMPTOMS**
AF can also be silent¹⁸

WHO IS AT RISK?

AF is a common age-related arrhythmia^{12,13,19}

40+



1 in 4 ADULTS

40 YEARS AND OLDER develop AF in their lifetime¹³

65+



Nearly 8 out of 10 ADULTS

suffering from (or diagnosed with) AF or Atrial Flutter **ARE 65 YEARS OLD OR OLDER³**

AF INCREASES THE RISK OF OTHER LIFE-THREATENING CONDITIONS¹⁰

5x Increase heart failure



2.4x Increase stroke



2x Increase cardiovascular mortality



Estimates suggest that by 2030, the number of people with AF is expected to increase up to 70%,²⁰ leading to more strokes, hospitalizations and outpatient visits.



280K-340K NEW ISCHEMIC STROKES



3.5-4 MILLION HOSPITALIZATIONS FOR AF



100-120 MILLION OUTPATIENT VISITS

BURDEN OF AF ON PATIENTS

Patients often report impaired function and disruption of everyday activities, impacting considerably on quality of life.^{16,21}



19% IMPAIRMENT IN FUNCTIONAL STATUS²²

25% DISRUPTION TO DAILY ACTIVITIES²²

UP TO 47% REDUCTION IN QUALITY OF LIFE²²⁻²³

BURDEN ON HEALTHCARE SYSTEMS


The economic burden of AF places a critical financial impact on healthcare systems across Europe.⁵⁻⁸

IN FRANCE, GERMANY, ITALY, the UK over **11M** PATIENTS ARE ESTIMATED

the reported **COSTS** range from **€660M-€3,286M**

EARLY DETECTION IS KEY

Early detection and diagnosis of AF may help improve patient outcomes, since long history and duration of AF have been associated with recurrence.²⁴⁻²⁵



TACKLING AF

Improved awareness of AF

- To support earlier detection and diagnosis and reduce need for costly emergency care.
- To support better treatment and management of AF and to avoid the development of complications.

Education and support for patients & carers

- To help patients and their carers manage their condition more effectively with the goal of improving quality of life and to reduce the need for medical interventions.

REFERENCES

1. The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic across Europe, 2018 Full Report, Biosense Webster.
2. Iaizzo PA (2015). Handbook of Cardiac Anatomy, Physiology, and Devices. Springer Science+Business Media, LLC: Switzerland
3. Global Burden of Disease Collaborative Network (2016) Global Burden of Disease Study 2016 (GBD 2016) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2017. Accessed April 2018. Available from <http://ghdx.healthdata.org/gbd-results-tool>
4. Rahman F et al. Nat Rev Cardiol 11 (11): 639-654.
5. McBride D et al. (2009) Value Health 12 (2): 293-301.
6. Ball J et al. (2013) Int J Cardiol 167 (5): 1807-1824.
7. Cotte FE et al. (2016) Europace 18 (4): 501-507.
8. Stewart S et al. (2004) Heart 90 (3): 286-292.
9. Menke J et al. (2010) Am J Cardiol 105 (4): 502-510.
10. Oduyayo A et al. (2016) BMJ 354:14482.
11. Calkins H et al. (2017) Heart Rhythm 14 (10): e275-e444.
12. Kirchhof P et al. (2016) Eur Heart J 37 (38): 2893-2962.
13. Lloyd-Jones DM et al. (2004) Circulation 110 (9): 1042-1046.
14. Naser N et al. (2017) Mater Sociomed 29 (4): 231-236.
15. Nazli C et al. (2016) Anatol J Cardiol 16 (4): 250-255.
16. Rho RW et al. (2005) Prog Cardiovasc Dis 48 (2): 79-87, 50.
17. Guerra F et al. (2017) Europace 19 (12): 1922-1929.
18. Rienstra M et al. (2012) Circulation 125 (23): 2933-2943.
19. Heeringa J et al. (2006) Eur Heart J 27 (8): 949-953.
20. Zoni-Berisso M et al. (2014) Clin Epidemiol 6: 213-220.
21. Lip GY et al. (2014) Eur Heart J 35 (47): 3365-3376.
22. Dorian P et al. (2000). J Am Coll Cardiol 36 (4): 1303-1309.
23. Van den Berg MP et al. (2001) Eur Heart J 22 (3): 247-253.
24. Scherr D et al. (2015) Circ Arrhythm Electrophysiol 8 (1): 18-24.
25. Pathak RK et al. (2014) J Am Coll Cardiol 64 (21): 2222-2231.
26. Nieuwlaet R et al. (2008) Eur Heart J 29 (9): 1181-1189.

A copy of the full report can be downloaded www.jnjmedicaldevices.com/en-EMEA